ERYTECH Pharma S.A. Logo

ERYTECH Pharma S.A.

Develops red blood cell-based therapies for cancer and orphan diseases.

ERYP | PA

Overview

Corporate Details

ISIN(s):
FR0010417360 (+2 more)
LEI:
969500U8ZZCODU8A9374
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON

Description

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-18 07:00
Informations privilégiées / Autres communiqués
French 168.4 KB
2025-06-18 07:00
Inside Information / Other news releases
English 169.6 KB
2025-06-12 18:00
Informations privilégiées / Autres communiqués
French 173.5 KB
2025-06-12 18:00
Inside Information / Other news releases
English 180.8 KB
2025-06-05 07:00
Informations privilégiées / Autres communiqués
French 116.9 KB
2025-06-05 07:00
Inside Information / Other news releases
English 121.1 KB
2025-05-22 18:00
Inside Information / Other news releases
English 118.8 KB
2025-05-22 18:00
Informations privilégiées / Autres communiqués
French 116.6 KB
2025-05-05 07:00
Inside Information / Other news releases
English 118.8 KB
2025-05-05 07:00
Informations privilégiées / Autres communiqués
French 118.4 KB
2025-04-24 18:00
Inside Information / Other news releases
English 155.0 KB
2025-04-24 18:00
Informations privilégiées / Autres communiqués
French 125.4 KB
2025-03-14 17:45
Inside Information / Other news releases
English 168.3 KB
2025-03-14 17:45
Informations privilégiées / Autres communiqués
French 172.5 KB
2025-03-06 17:56
Informations privilégiées / Autres communiqués
French 159.2 KB

Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ERYTECH Pharma S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-23 N/A Other Other 3,697,533 2,255,495.13 EUR
2023-06-23 N/A Other Other 71,839 43,821.79 EUR
2023-06-23 N/A Other Other 54,862 33,465.82 EUR

Peer Companies

Camp4 Therapeutics Corp Logo
Develops RNA-based therapeutics to amplify protein expression for genetic diseases.
United States of America
CAMP
Camurus Logo
Develops and commercializes long-acting medicines for severe and chronic diseases.
Sweden
CAMX
Candel Therapeutics, Inc. Logo
Develops viral immunotherapies to activate the immune system to fight cancer.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
Israel
CANF
Cannabotech Ltd. Logo
Develops therapies by integrating cannabinoids and medicinal mushroom extracts.
Israel
CNTC
Cannovum Cannabis AG Logo
Licensed importer, wholesaler, and manufacturer of medical cannabis products.
Germany
27N0
Cantargia Logo
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
Sweden
CANTA
Cantourage Group SE Logo
Produces and distributes EU-compliant medical cannabis from international partners.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
A clinical-stage biotech developing cell and exosome-based biologics for serious diseases.
United States of America
CAPR
A clinical-stage biotech developing regenerative medicines for heart failure.
United Kingdom
N/A

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.